Recombinant Human Galanin protein (mFc Tag)

• Home
• Products
• Fusion Proteins
• AuthentiKine ELISA Kits
• Recombinant Human Galanin protein (mFc Tag) (Eg3984)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

mFc Tag

Activity

not tested

Cat no : Eg3984

---

Validation Data Gallery

• 

  Purity of Recombinant Human Galanin was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human Galanin protein Ala20-Ser123 (Accession# P22466) with a mouse IgG Fc tag at the C-terminus.
• GeneID: 51083
• Accession: P22466
• PredictedSize: 38.1 kDa
• SDS-PAGE: 38-45 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Galanin is expressed in the central nervous system, including the hypothalamus, pituitary, and the spinal cord, and colocalizes with other neuronal peptides within neurons. It is also found in various tissues such as the gastrointestinal tract and pancreas, demonstrating its importance and versatility for neuro-hormonal homeostasis. Dysregulation of galanin and its related peptides has been implicated in various neuroendocrine conditions such as nociception, Alzheimer's disease, seizures, eating disorders, alcoholism, diabetes, and spinal cord conditions.

References:

1.Duan J. et al. (2022). Nat Commun. 13(1):1364. 
2.Zhu S. et al. (202). Front Endocrinol (Lausanne). 13:1019943.